WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002028871) PLATINUM COMPLEXES AS ANTITUMOR AGENTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/028871    International Application No.:    PCT/US2001/030838
Publication Date: 11.04.2002 International Filing Date: 02.10.2001
Chapter 2 Demand Filed:    19.04.2002    
IPC:
C07F 15/00 (2006.01)
Applicants: ANORMED INC. [CA/CA]; No. 200-20353 64th Avenue Langley, BC V2Y 1N5 (CA) (For All Designated States Except US).
WONG, Ernest, S., Y. [CA/CA]; (CA) (For US Only).
GIANDOMENICO, Christen, M. [US/US]; (US) (For US Only)
Inventors: WONG, Ernest, S., Y.; (CA).
GIANDOMENICO, Christen, M.; (US)
Agent: MURASHIGE, Kate, H.; Morrison & Foerster LLP Suite 500 3811 Valley Center Drive San Diego, CA 92130-2332 (US)
Priority Data:
09/678,595 04.10.2000 US
Title (EN) PLATINUM COMPLEXES AS ANTITUMOR AGENTS
(FR) COMPLEXES DE PLATINE TENANT LIEU D'AGENTS ANTITUMORAUX
Abstract: front page image
(EN)The present invention relates to platinum antitumor drugs. In particular, it relates to platinum complexes having formula Ia or Ib or a pharmaceutically acceptable salt thereof wherein each A is independently an anion; each B is independently halo, hydroxy, carboxylate, carbamate or a carbonate ester, Z is a substituted 5- or 6-membered, heterocyclic moiety wherein at least one substituent sterically hinders access of the Pt atom to a DNA strand of a tumor cell, and wherein Z is other than pyridine; and X is NH¿3? or mono- or dialkyl substituted NH¿3?; which are active against cancer cells and have improved aqueous solubility and activity.
(FR)L'invention concerne des médicaments antitumoraux à base de platine, et en particulier des complexes de platine de formule Ia ou Ib, y compris les sels pharmaceutiquement acceptables de ces composés. Dans lesdites formules, A est indépendamment un anion, chaque B est indépendamment halo, hydroxy, carboxylate, carbamate ou un ester de carbonate, Z est une fraction hétérocyclique substituée à 5 ou 6 éléments, sachant qu'au moins un substituant produit un effet d'encombrement stérique pour l'accès de l'atome de Pt à un brin d'ADN de cellule tumorale, et Z est autre que pyridine; enfin, X est NH¿3? ou NH¿3? à substitution mono- ou dialkyle. Les composés considérés agissent contre les cellules cancéreuses et présentent une solubilité et une activité aqueuse améliorée.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)